Toleranzia AB appoints SKMG as new Certified Adviser
28 November - 2024
Toleranzia AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding the service as Certified Adviser. SKMG will take over as Certified Adviser on December 1, 2024. Until then, Mangold Fondkommission AB will continue to hold the assignment as Certified Adviser for the company.
For further information, please contact
Charlotte Fribert – CEO, Toleranzia AB
Tel: +46 763 19 98 98
E-mail: charlotte.fribert@toleranzia.com
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.